August 17th, 2021 – Mycenax Biotech Inc. and Cytiva announced their partnership to enable Taiwan’s first continuous manufacturing process development satellite laboratory today. Mycenax’s commitment to providing the best manufacturing service and Cytiva’s dedication to advancing and accelerating therapeutics development allow both companies to strive and establish strategic relations. Cytiva’s laboratory equipment, including Xcellerex XDR – single-use stirred-tank bioreactor, WAVE bioreactor, and AKTA protein purification system, will be installed in Mycenax’s microbial process development laboratory in Zhubei City to further expand its development capability of continuous process technology. The laboratory will also provide relevant training courses to cultivate future talents for biopharmaceutical industry customers. This platform will be deployed in both Mycenax’s GMP facilities, enhancing the international competitiveness and satisfying the needs of our customers.
Taiwan’s First Continuous Manufacturing Process Development Satellite Laboratory
“This partnership authorized the first continuous platform laboratory in Taiwan, which is highly indicative of the development of biopharmaceutical technology” says Jeff Wang, Cytiva’s Business Head of Taiwan. “Mycenax is the only CDMO company in Taiwan that focuses solely on developing and manufacturing biological drugs. In line with Cytiva's mission to comprehensively improve our customers' manufacturing processes and promote medical development, we are working together to empower the development and production of innovative medicines to benefit patients worldwide. We hope this joint laboratory will encourage more companies in the industry to improve process efficiency and practice commercial mass production.”
“Mycenax has been engaging in continuous process development since 2017,” says Dr. Pei-Jiun Chen, CEO of Mycenax. “The biosimilar drug produced through this project became the first in the world to enter phase I clinical trial in the EU in March of 2019. With rich experience and knowledge, this cooperation with Cytiva will bring new and upgraded continuous process development services to our customers. The upgraded services will reduce manufacturing time for biological drugs and purification costs by 40%. It will significantly improve production efficiency and order capacity, making process operation more flexible. Given the global wave of biopharmaceutical development and the national policy support for the development of the CDMO industry, Mycenax’s technology investment is highly symbolic and is expected to bring growth to Taiwan's biopharmaceutical industry.”
Cytiva's Continuous Platform Automation Solution
As technology advances in the global industry, biopharmaceutical companies need to switch from labor-intensive systems to automation controls while complying with USFDA and EMA regulations. Continuous process technology has been plateauing in large-scale production of biopharmaceutical factories; therefore, Cytiva uses software control to connect the original single-point workstation with automatic feedback to achieve effective integration, improving the efficiency of the process. This solution will reduce facility space, on-site labor, and material costs significantly while providing flexibility to process operations. Cytiva’s solution will contribute to the development of commercial mass production processes, increasing Taiwan’s opportunity to receive international orders and strengthening the momentum of Taiwan’s biopharmaceutical development.
About Cytiva
Cytiva is a global life sciences pioneer dedicated to advancing and accelerating therapeutics development, with over 8000 employees in more than 40 countries. As a trusted partner for many customers, Cytiva focuses on life sciences and biotechnology research to develop vaccines, biological drugs, and novel cell and gene therapies. By improving production processes’ speed, efficiency, and capabilities, Cytiva develops and produces transformative drugs and treatments that benefit patients worldwide. To learn more, visit www.cytiva.com.
About Mycenax
Mycenax Biotech Inc. is the first CDMO company in Taiwan leading in CMC (chemistry, manufacturing, and control) development and specializing in manufacturing biological drugs. The company’s core value is to have a regulatory and market competitive bio-drug development technology and cGMP manufacturing plant to link research and development results with the commercialization of drugs. Our goal is to develop manufacturing services in Taiwan for the upstream and downstream industries. To learn more, visit http://www.mycenax.com.tw.
August 17th, 2021 – Mycenax Biotech Inc. and Cytiva announced their partnership to enable Taiwan’s first continuous manufacturing process development satellite laboratory today. Mycenax’s commitment to providing the best manufacturing service and Cytiva’s dedication to advancing and accelerating therapeutics development allow both companies to strive and establish strategic relations. Cytiva’s laboratory equipment, including Xcellerex XDR – single-use stirred-tank bioreactor, WAVE bioreactor, and AKTA protein purification system, will be installed in Mycenax’s microbial process development laboratory in Zhubei City to further expand its development capability of continuous process technology. The laboratory will also provide relevant training courses to cultivate future talents for biopharmaceutical industry customers. This platform will be deployed in both Mycenax’s GMP facilities, enhancing the international competitiveness and satisfying the needs of our customers.
Taiwan’s First Continuous Manufacturing Process Development Satellite Laboratory
“This partnership authorized the first continuous platform laboratory in Taiwan, which is highly indicative of the development of biopharmaceutical technology” says Jeff Wang, Cytiva’s Business Head of Taiwan. “Mycenax is the only CDMO company in Taiwan that focuses solely on developing and manufacturing biological drugs. In line with Cytiva's mission to comprehensively improve our customers' manufacturing processes and promote medical development, we are working together to empower the development and production of innovative medicines to benefit patients worldwide. We hope this joint laboratory will encourage more companies in the industry to improve process efficiency and practice commercial mass production.”
“Mycenax has been engaging in continuous process development since 2017,” says Dr. Pei-Jiun Chen, CEO of Mycenax. “The biosimilar drug produced through this project became the first in the world to enter phase I clinical trial in the EU in March of 2019. With rich experience and knowledge, this cooperation with Cytiva will bring new and upgraded continuous process development services to our customers. The upgraded services will reduce manufacturing time for biological drugs and purification costs by 40%. It will significantly improve production efficiency and order capacity, making process operation more flexible. Given the global wave of biopharmaceutical development and the national policy support for the development of the CDMO industry, Mycenax’s technology investment is highly symbolic and is expected to bring growth to Taiwan's biopharmaceutical industry.”
Cytiva's Continuous Platform Automation Solution
As technology advances in the global industry, biopharmaceutical companies need to switch from labor-intensive systems to automation controls while complying with USFDA and EMA regulations. Continuous process technology has been plateauing in large-scale production of biopharmaceutical factories; therefore, Cytiva uses software control to connect the original single-point workstation with automatic feedback to achieve effective integration, improving the efficiency of the process. This solution will reduce facility space, on-site labor, and material costs significantly while providing flexibility to process operations. Cytiva’s solution will contribute to the development of commercial mass production processes, increasing Taiwan’s opportunity to receive international orders and strengthening the momentum of Taiwan’s biopharmaceutical development.
About Cytiva
Cytiva is a global life sciences pioneer dedicated to advancing and accelerating therapeutics development, with over 8000 employees in more than 40 countries. As a trusted partner for many customers, Cytiva focuses on life sciences and biotechnology research to develop vaccines, biological drugs, and novel cell and gene therapies. By improving production processes’ speed, efficiency, and capabilities, Cytiva develops and produces transformative drugs and treatments that benefit patients worldwide. To learn more, visit www.cytiva.com.
About Mycenax
Mycenax Biotech Inc. is the first CDMO company in Taiwan leading in CMC (chemistry, manufacturing, and control) development and specializing in manufacturing biological drugs. The company’s core value is to have a regulatory and market competitive bio-drug development technology and cGMP manufacturing plant to link research and development results with the commercialization of drugs. Our goal is to develop manufacturing services in Taiwan for the upstream and downstream industries. To learn more, visit http://www.mycenax.com.tw.